Skip to content

Ponoi II Management, LLC

Follow

13F filer, CIK 1746488, San Francisco, CA

Ponoi II Management, LLC reported $67,488,000 across 4 holdings for the quarter ended 2021-09-30, in a 13F-HR filed 2021-11-12.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0000950123-21-014993

Period
2021-09-30
Reported value
$67.5M
Holdings
4
Top 10 weight
100%
New
0
Sold out
1

Largest buys vs the previous quarter

None.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
CONSTELLATION PHARMACEUTICALexited-1,574,229-$53.2M
NRIXreduced-124,700-$3.74M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2021

Share positions as resolved from 13F-HR 0000950123-21-014993, largest first. % of portfolio is the value over $67,488,000, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
NGM BIOPHARMACEUTICALS INCNGM BIOPHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2019Q4: restricted; 2020Q1: restricted; 2020Q2: restricted; 2020Q3: restricted; 2020Q4: 1,298,908 shares; 2021Q1: 1,298,908 shares; 2021Q2: 1,298,908 shares; 2021Q3: 1,298,908 shares 1,298,908$27.3M40.46%0
RVMDREVOLUTION MEDICINES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2019Q4: restricted; 2020Q1: restricted; 2020Q2: restricted; 2020Q3: restricted; 2020Q4: 685,011 shares; 2021Q1: 685,011 shares; 2021Q2: 685,011 shares; 2021Q3: 685,011 shares 685,011$18.8M27.92%0Timeline
NRIXNURIX THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2019Q4: restricted; 2020Q1: restricted; 2020Q2: restricted; 2020Q3: restricted; 2020Q4: 686,274 shares; 2021Q1: 686,274 shares; 2021Q2: 686,274 shares; 2021Q3: 561,574 shares 561,574$16.8M24.93%-124,700Timeline
RAPT THERAPEUTICS INCRAPT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2019Q4: restricted; 2020Q1: restricted; 2020Q2: restricted; 2020Q3: restricted; 2020Q4: 145,401 shares; 2021Q1: 145,401 shares; 2021Q2: 145,401 shares; 2021Q3: 145,401 shares 145,401$4.51M6.69%0

Sold out in Q3 2021

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
CONSTELLATION PHARMACEUTICALCONSTELLATION PHARMACEUTICAL1,574,229$53.2Mshares

How Q3 2021 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0000950123-21-014993 base2021-11-12acceptance time not in the bulk data set